REGN Q3 2017 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+23.0% YoY

Gross Profit

$1.4B90.5% margin

Operating Income

$560M37.3% margin

Net Income

$388M25.9% margin

EPS (Diluted)

$3.32

QoQ Revenue Growth

+2.1%

Cash Flow

Operating Cash Flow

$415M

Free Cash Flow

$355M

Stock-Based Comp.

$125M

Balance Sheet

Total Assets

$8.7B

Total Liabilities

$2.6B

Stockholders' Equity

$6.1B

Cash & Equivalents

$792M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$1.2B	+23.0%
Gross Profit	$1.4B	$1.1B	+18.3%
Operating Income	$560M	$363M	+54.3%
Net Income	$388M	$265M	+46.6%

Revenue Segments

Antibody Collaboration

$162M66%

Immuno-oncology Agreement

$83M34%